Clinical Trial Update: Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP

View source ↗

Summary

A five-year follow-up economic analysis comparing PCI with Taxus paclitaxel-eluting stents against coronary artery bypass grafting for multivessel coronary arte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multivessel Coronary Artery Disease

Drugs mentioned

• TAXUS Paclitaxel-Eluting Stent (paclitaxel-eluting stent)

Snippet

Sponsor: Medical University of Vienna | Conditions: Multivessel Coronary Artery Disease | Status: COMPLETED